Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Mother and Child summed up the results of work in the 1st quarter

4/28/23 MDMG

VKontakte's first NFT collection sold out in 30 minutes

4/28/23 VKCO

First Solar reported for 3 months of 2023

4/28/23 FSLR

Abbott bought Cardiovascular Systems

4/28/23 CSII

Abbott bought Cardiovascular Systems

4/28/23 ABT

Mondelēz International reported for 3 months of 2023

4/28/23 MDLZ

Gilead reports on 3 months of 2023

4/28/23 GILD

Amazon reported for 3 months of 2023

4/28/23 AMZN

Intel reported for 3 months of 2023

4/28/23 INTC

EL5-Energo in Q1 decreased energy generation by 6.7%

4/28/23 ELFV